Showing results (221-230 of 364) with videos related to
Sort By:
Pageof 37
Radiation Research|February 1, 1997
Stroma-free human hemoglobin A decreases R3230Ac rat mammary adenocarcinoma blood flow and oxygen partial pressureJ S Hahn, R D Braun, M W Dewhirst, et al.Blood Cancer Journal|September 10, 2013
Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapyL Qin, B D Smith, H-L Tsai, et al.Cancer Medicine|January 23, 2020
Race, tumor location, and disease progression among low-risk prostate cancer patientsJustin G Mygatt, Jennifer Cullen, Samantha A Streicher, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2006
Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762)Stuart M Lichtman, Donna Hollis, Antonius A Miller, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2005
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13William P Peters, Gary L Rosner, James J Vredenburgh, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871Lionel D Lewis, Antonius A Miller, Gary L Rosner, et al.European Urology|December 4, 2014
A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate CancerJennifer Cullen, Inger L Rosner, Timothy C Brand, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemiaDavid A Rizzieri, Valerie K Ibom, Joseph O Moore, et al.Journal of the National Cancer Institute|September 22, 2005
MGMT promoter methylation and field defect in sporadic colorectal cancerLanlan Shen, Yutaka Kondo, Gary L Rosner, et al.International Journal of Radiation Oncology, Biology, Physics|November 26, 1999
The treatment of high-grade soft tissue sarcomas with preoperative thermoradiotherapyL R Prosnitz, P Maguire, J M Anderson, et al.Pageof 37